Condition: ER-positive Breast Cancer · HER2-negative Breast Cancer · Stage IIB Breast Cancer · Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
This is an international, multi-center, randomised, open label, superiority phase III trial of elacestrant vs standard endocrine therapy in patients with ER+/HER2- breast cancer and ctDNA relapse. During the ctDNA screening phase, patients will be tested at different timepoints to detect the presence of ctDNA in their blood. Patients who are found to be ctDNA-positive and have no evidence of distant metastasis, will be randomised 1:1 between standard endocrine treatment (the same they were receiving when tested ctDNA positive) versus elacestrant, provided they meet all eligibility criteria. After completion of the protocol treatment period, treatment will be left at the discretion of the treating physician.
This description comes directly from the study's public registry record.
EORTC HQ · +32 2 774 16 11 · eortc@eortc.org
Always discuss trial participation with your own doctor first.
| Institut Jules Bordet | Anderlecht, Belgium | Recruiting |
| Cliniques Universitaires Saint-Luc | Brussels, Belgium | Recruiting |
| Hopital Universitaire Brugmann | Brussels, Belgium | Recruiting |
| Grand Hopital de Charleroi - Site Notre Dame | Charleroi, Belgium | Recruiting |
| CHU Helora Pole Hospitalier Jolimont - Hopital Jolimont | Haine-Saint-Paul, Belgium | Recruiting |
| AZ Groeninge Kortrijk - Campus Kennedylaan | Kortrijk, Belgium | Recruiting |
| U.Z. Leuven - Campus Gasthuisberg | Leuven, Belgium | Recruiting |
| CHU Site Sainte-Elisabeth-UCL Namur | Namur, Belgium | Recruiting |
| AZ Delta - Campus Rumbeke | Roeselare, Belgium | Recruiting |
| Centre Hospitalier Regional Verviers | Verviers, Belgium | Recruiting |
| German Oncology Center | Limassol, Cyprus | Recruiting |
| Bank Of Cyprus Oncology Centre | Stróvolos, Cyprus | Recruiting |
+ 97 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05512364